Back to mobile site

H.C. Wainwright Reiterates Buy Rating on ArriVent BioPharma (AVBP)

June 30, 2025 6:50 AM EDT Send to a Friend
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $40.00 price target on ArriVent BioPharma (NASDAQ: AVBP).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login